A Novel Compound for Targeted Treatment of CBF Leukemia
一种靶向治疗 CBF 白血病的新型化合物
基本信息
- 批准号:10253924
- 负责人:
- 金额:$ 146.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:Animal Disease ModelsAnimal ModelBiochemicalBiological AssayBone MarrowBone Marrow TransplantationCell Culture TechniquesCell ExtractsCessation of lifeChemicalsChromosomal translocationChromosome inversionCore-Binding FactorDevelopmentDoseDrug KineticsDrug TargetingHemorrhageIn VitroInfectionLeadLeukocytesLifeMalignant NeoplasmsModelingMolecularMolecular AbnormalityMusPharmaceutical ChemistryPharmaceutical PreparationsPlayProteinsRecurrenceResearchResearch PersonnelRoleScientistStudy modelsSubgroupSurvival RateTherapeutics for Rare and Neglected DiseasesTimebasechemotherapyfusion geneimprovedinhibitor/antagonistkidney dysfunctionlead optimizationleukemialeukemogenesisnovelrare cancerside effectsmall molecule librariesstandard caretargeted treatment
项目摘要
Leukemia is a bone marrow cancer involving developing white blood cells and often is associated with specific, recurrent chromosome translocations and inversions that generate fusion genes, which play critical roles in leukemogenesis.
In this project, targeted treatments are being developed for a subgroup of leukemia based on current understanding of how leukemia develops at the molecular level. The core binding factor (CBF) subgroup of leukemia contains CBF fusion genes that have been shown to play critical roles in leukemia development. Current treatments for CBF leukemia are not optimal, with long-term survival at 50 percent. The research team conducted a small chemical library screen to find inhibitors that block CBF protein interactions. Through biochemical, cell culture and animal model studies, they identified three chemically related lead compounds. One of these compounds showed leukemia reduction capability similar to standard chemotherapy drugs in preliminary studies in a mouse CBF leukemia model.
TRND researchers have successfully optimized and demonstrated the utility of the animal disease model and showed for the first time that the initial lead compound is effective in the model as monotherapy. TRND scientists performed medicinal chemistry optimization to identify a compound with significantly improved pharmacokinetics and tolerability after repeat dosing in mice. The collaborator developed a new in vitro efficacy assay, using cells extracted from bone marrow, to support the medicinal chemistry. The optimized lead compound was evaluated in the animal disease model but was less effective than the initial lead.
白血病是一种涉及发育中的白色血细胞的骨髓癌,通常与产生融合基因的特异性、复发性染色体易位和倒位相关,融合基因在白血病发生中起关键作用。
在这个项目中,基于目前对白血病如何在分子水平上发展的理解,正在为白血病的一个亚组开发靶向治疗。白血病的核心结合因子(CBF)亚组包含CBF融合基因,已被证明在白血病的发展中发挥关键作用。目前CBF白血病的治疗方法并不理想,长期生存率为50%。研究小组进行了一个小型化学库筛选,以寻找阻断CBF蛋白相互作用的抑制剂。通过生物化学,细胞培养和动物模型研究,他们确定了三种化学相关的铅化合物。在小鼠CBF白血病模型的初步研究中,这些化合物之一显示出与标准化疗药物相似的白血病减少能力。
TRND的研究人员已经成功地优化和证明了动物疾病模型的实用性,并首次证明了初始先导化合物作为单一疗法在模型中是有效的。TRND科学家进行了药物化学优化,以确定在小鼠中重复给药后具有显著改善的药代动力学和耐受性的化合物。该合作者开发了一种新的体外疗效测定法,使用从骨髓中提取的细胞,以支持药物化学。在动物疾病模型中评估了优化的先导化合物,但其效果不如初始先导化合物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Philip Sanderson其他文献
Philip Sanderson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Philip Sanderson', 18)}}的其他基金
Deuterated Analogs of Praziquantel for Treatment of Schistosomiasis
吡喹酮氘代类似物治疗血吸虫病
- 批准号:
9205581 - 财政年份:
- 资助金额:
$ 146.99万 - 项目类别:
BMP Inhibitors to Treat Fibrodysplasia Ossificans Progressiva
BMP 抑制剂治疗进行性骨化性纤维发育不良
- 批准号:
10469236 - 财政年份:
- 资助金额:
$ 146.99万 - 项目类别:
BMP Inhibitors to Treat Fibrodysplasia Ossificans Progressiva
BMP 抑制剂治疗进行性骨化性纤维发育不良
- 批准号:
9551296 - 财政年份:
- 资助金额:
$ 146.99万 - 项目类别:
Therapy for Fuchs Endothelial Corneal Dystrophy
福克斯内皮性角膜营养不良的治疗
- 批准号:
10469255 - 财政年份:
- 资助金额:
$ 146.99万 - 项目类别:
Therapy for Fuchs Endothelial Corneal Dystrophy
福克斯内皮性角膜营养不良的治疗
- 批准号:
10259363 - 财政年份:
- 资助金额:
$ 146.99万 - 项目类别:
Antifibrotic Therapy for the Treatment of Pulmonary Hypertension
治疗肺动脉高压的抗纤维化疗法
- 批准号:
10253934 - 财政年份:
- 资助金额:
$ 146.99万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 146.99万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 146.99万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 146.99万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 146.99万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 146.99万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 146.99万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 146.99万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 146.99万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 146.99万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 146.99万 - 项目类别:
Grant-in-Aid for Early-Career Scientists